Spots Global Cancer Trial Database for otorhinolaryngologic diseases
Every month we try and update this database with for otorhinolaryngologic diseases cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
| Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients | NCT01490476 | Neurofibromatos... | RAD001 | 15 Years - | Assistance Publique - Hôpitaux de Paris | |
| Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer | NCT05388773 | Oropharynx Canc... | therapeutic con... laboratory biom... quality-of-life... intensity-modul... Cisplatin Carboplatin | 18 Years - | University of Pittsburgh | |
| Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | NCT04124198 | Oropharynx Canc... Oropharynx Squa... Carcinoma, Squa... Carcinoma Oropharyngeal N... Neoplasms, Squa... Neoplasms, Glan... Neoplasms by Hi... Pharyngeal Neop... Otorhinolaryngo... Head and Neck N... Neoplasms by Si... Otorhinolaryngo... Pharyngeal Dise... Papillomavirus ... Virus Diseases DNA Virus Infec... Tumor Virus Inf... Quality of Life | Intensity-Modul... Cisplatin Nimorazole. Transoral Robot... | 18 Years - | Rigshospitalet, Denmark | |
| Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis | NCT03401229 | Nasal Polyposis | Benralizumab 30... Matching placeb... | 18 Years - 75 Years | AstraZeneca | |
| Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | NCT04124198 | Oropharynx Canc... Oropharynx Squa... Carcinoma, Squa... Carcinoma Oropharyngeal N... Neoplasms, Squa... Neoplasms, Glan... Neoplasms by Hi... Pharyngeal Neop... Otorhinolaryngo... Head and Neck N... Neoplasms by Si... Otorhinolaryngo... Pharyngeal Dise... Papillomavirus ... Virus Diseases DNA Virus Infec... Tumor Virus Inf... Quality of Life | Intensity-Modul... Cisplatin Nimorazole. Transoral Robot... | 18 Years - | Rigshospitalet, Denmark | |
| Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis | NCT03401229 | Nasal Polyposis | Benralizumab 30... Matching placeb... | 18 Years - 75 Years | AstraZeneca | |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
